<SEC-DOCUMENT>0001213900-20-042142.txt : 20201211
<SEC-HEADER>0001213900-20-042142.hdr.sgml : 20201211
<ACCEPTANCE-DATETIME>20201211060245
ACCESSION NUMBER:		0001213900-20-042142
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20201211
DATE AS OF CHANGE:		20201211

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-239010
		FILM NUMBER:		201382161

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AYTU BIOSCIENCE, INC
		CENTRAL INDEX KEY:			0001385818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				470883144
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112
		BUSINESS PHONE:		(720) 437-6580

	MAIL ADDRESS:	
		STREET 1:		373 INVERNESS PARKWAY
		STREET 2:		SUITE 206
		CITY:			ENGLEWOOD
		STATE:			CO
		ZIP:			80112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AYTU BIOSCIENCE, INC.
		DATE OF NAME CHANGE:	20150609

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Rosewind CORP
		DATE OF NAME CHANGE:	20070110
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>ea131471-fwp_aytubioscience.htm
<DESCRIPTION>FREE WRITING PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Free Writing Prospectus dated December&nbsp;11,
2020 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 433 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Relating to the Preliminary Prospectus
Supplement dated December&nbsp;10, 2020 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration&nbsp;Statement&nbsp;No.&nbsp;No.
333-239010</B></P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Aytu BioScience Increases
Previously Announced Bought Deal Offering to $25.0 Million</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ENGLEWOOD, CO / ACCESSWIRE / December 10, 2020 /</B>&nbsp;Aytu
BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant
patient needs, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced
public offering and purchase on a firm commitment basis 4,166,667 shares of common stock of the Company, at a price to the public
of $6.00 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December
15, 2020, subject to satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">H.C. Wainwright &amp; Co. is acting as the sole book-running
manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company also has granted to the underwriter a 30-day option
to purchase up to an additional 625,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
The gross proceeds to Aytu, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise
of the underwriter&rsquo;s option to purchase additional common stock, are expected to be approximately $25.0 million. The Company
intends to use the net proceeds from this offering for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The shares of common stock are being offered by the Company
pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-239010) previously filed with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) on June 8, 2020, and declared effective by the SEC on June 17, 2020. The offering
of the shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective
registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of,
the offering has been filed with the SEC and is available on the SEC&rsquo;s website at http://www.sec.gov. A final prospectus
supplement and the accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic
copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at
http://www.sec.gov or by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone
at (646) 975-6996 or e-mail at placements@hcwco.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or
a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws
of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Aytu BioScience, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu BioScience is a commercial-stage specialty pharmaceutical
company focused on commercializing novel products that address significant patient needs. Aytu currently markets a portfolio of
prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto&reg;,
the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or &quot;Low T&quot;), (ii)
ZolpiMist&reg;, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra&reg; XR, the only FDA-approved 12-hour
codeine-based antitussive syrup. The pediatric portfolio includes (i) Cefaclor, a second-generation cephalosporin antibiotic suspension;
(ii) Karbinal&reg; ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions;
and (iii) Poly-Vi-Flor&reg; and Tri-Vi-Flor&reg;, two complementary prescription fluoride-based supplement product lines containing
combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. Aytu also distributes
a COVID-19 IgG/IgM rapid antibody test and rapid antigen test. These tests are used separately in the rapid, qualitative diagnostic
assessment of the 2019 Novel Coronavirus. Additionally, Aytu recently licensed worldwide rights to develop the Healight&trade;
technology platform. Healight is an investigational medical device being studied as a prospective treatment for COVID-19 and other
respiratory infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu operates a consumer health subsidiary, Innovus Pharmaceuticals,
Inc. (&quot;Innovus&quot;), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer
healthcare products designed to improve men's and women's health and vitality. Innovus commercializes numerous novel consumer health
products competing in large healthcare categories including diabetes, men's health, sexual wellness, respiratory health, and general
wellness. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's
proprietary Beyond Human&reg; marketing and sales platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aytu's strategy is to continue building its portfolio of revenue-generating
Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic
markets. For more information visit aytubio.com and visit innovuspharma.com to learn about Aytu's consumer healthcare products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of historical facts contained in this press release, are forward-looking
statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,''
''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,''
''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology.
All statements other than statements of historical facts contained in this presentation, are forward-looking statements, including
but not limited to any statements regarding the expected timetable for completing the proposed transaction, the results, effects,
benefits and synergies of the proposed transaction, future opportunities for the combined company, future financial performance
and condition, guidance and any other statements regarding Aytu's or Neos' future expectations, beliefs, plans, objectives, financial
conditions, assumptions or future events or performance. These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: market
and other conditions and the satisfaction of customary closing conditions related to the public offering and the intended use of
net proceeds from the public offering, failure to obtain the required votes of Neos' shareholders or Aytu's shareholders to approve
the transaction and related matters, the risk that a condition to closing of the proposed transaction may not be satisfied, that
either party may terminate the merger agreement or that the closing of the proposed transaction might be delayed or not occur at
all, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement
or completion of the transaction, the diversion of management time on transaction-related issues, the ultimate timing, outcome
and results of integrating the operations of Aytu and Neos, the effects of the business combination of Aytu and Neos, including
the combined company's future financial condition, results of operations, strategy and plans, the ability of the combined company
to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined
company to finance operations in the manner expected, regulatory approval of the transaction, risks relating to gaining market
acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of the combined
company's product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results,
of the combined company's ongoing and future clinical trials, the anticipated designs of the combined company's future clinical
trials, anticipated future regulatory submissions and events, the combined company's anticipated future cash position and future
events under current and potential future collaboration, the regulatory and commercial risks associated with introducing the Company&rsquo;s
distributed COVID-19 rapid tests, the accuracy of the COVID-19 rapid tests as compared to other COVID-19 tests, market acceptance
of the tests, the ability to obtain FDA approval or authorization for the tests, our ability to obtain sufficient tests to meet
consumer demand, if any, the manufacturers' ability to scale up manufacturing to meet customer demand, if any, reputation risks
if the tests are not as effective as anticipated, and that the current regulatory environment continues to permit the sale of the
tests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact for Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James Carbonara<BR>
Hayden IR<BR>
(646) 755-7412<BR>
<B>james@haydenir.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SOURCE:&nbsp;</B>Aytu BioScience, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
